secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001193125-22-025869
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme cuts workforce 53%, CEO/CSO depart amid clinical hold; pipeline pivots to COR588 and oncology
--------------------------------------------------------------------------------

- CEO Casey Lynch and CSO Stephen Dominy resigned Jan 28; COO/CFO Christopher Lowe appointed Interim CEO and director.
- Workforce reduced ~53% with expected annualized savings of $8.3M in 2022 and one-time costs of $1.9-$2.1M.
- Preliminary cash, cash equivalents & investments of $126.7M as of Dec 31, 2021 (unaudited).
- Pipeline: COR588 Phase 1 data expected Q2 2022; atuzaginstat IND for oral squamous cell carcinoma in Q1 2022; COR803 in IND-enabling studies.
- Atuzaginstat IND on clinical hold for Alzheimer's; company plans Phase 2 for COR588 after FDA interactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/d274026d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-025869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer